The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix

The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix.
Higher doses of the blood-thinner Plavix were no better at preventing love attacks, blood clots or passing than the law lower dose in patients who had received artery-opening stents, supplemental research shows. The higher dose - increase the usual amount - was tested in patients with "high platelet reactivity," meaning they failed to come back to the drug at lower doses prices. Plavix (clopidogrel) helps prevent clots from forming in patients who have insufficient platelet reactivity and who have had stents inserted to prop open blocked arteries.

But the brand-new study "doesn't support" physicians using the higher, 150-milligram dose of Plavix after stenting, according to cram lead author Dr Matthew Price, who presented the findings Tuesday at the annual get-together of the American Heart Association in Chicago. So, the study leaves an important question unanswered: How to deal with heart patients who don't respond well to Plavix? "It remains vacillating to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn as example. "It's an foremost study to have done but the key issues are that a significant proportion of the patients remained with steep platelet reactivity even after being on the higher dose".

Previous, smaller studies had indicated that Plavix might have more of an effect if the administer was doubled. "Platelet reactivity varies widely," noted Price, director of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a high-priced reactivity lay waste is associated with poorer outcomes after angioplasty and/or stenting. But until now, a inundate rise in the dose of Plavix "has not been tested in a large randomized clinical trial".